Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy.

A. Turhan, J. M. Connors, Paul Klimo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We evaluated the efficacy and toxicity of ketoconazole versus nystatin antimycotic prophylaxis in a prospective randomized study of 32 patients receiving intensive weekly outpatient combination chemotherapy for non-Hodgkin's lymphoma with crossover to the other drug if failure occurred. Thirteen patients were assigned to nystatin and 19 to ketoconazole. Fungal infections occurred in three patients receiving nystatin (16%) and one patient receiving ketoconazole (8%); one patient refused his assigned drug due to taste intolerance. Including the crossover courses of drug, the failure rate associated with ketoconazole was 6% while that for nystatin was 20% (p = 0.23). We favor ketoconazole as antifungal prophylaxis during antilymphoma chemotherapy because of at least equivalent and possibly superior efficacy, better acceptance by patients, easier administration, and systemic absorption.

Original languageEnglish (US)
Pages (from-to)355-359
Number of pages5
JournalAmerican journal of clinical oncology
Volume10
Issue number4
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Nystatin
Ketoconazole
Mycoses
Lymphoma
Drug Therapy
Pharmaceutical Preparations
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Outpatients
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy. / Turhan, A.; Connors, J. M.; Klimo, Paul.

In: American journal of clinical oncology, Vol. 10, No. 4, 01.01.1987, p. 355-359.

Research output: Contribution to journalArticle

@article{257488ca60d04d6baec4a95a808dab63,
title = "Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy.",
abstract = "We evaluated the efficacy and toxicity of ketoconazole versus nystatin antimycotic prophylaxis in a prospective randomized study of 32 patients receiving intensive weekly outpatient combination chemotherapy for non-Hodgkin's lymphoma with crossover to the other drug if failure occurred. Thirteen patients were assigned to nystatin and 19 to ketoconazole. Fungal infections occurred in three patients receiving nystatin (16{\%}) and one patient receiving ketoconazole (8{\%}); one patient refused his assigned drug due to taste intolerance. Including the crossover courses of drug, the failure rate associated with ketoconazole was 6{\%} while that for nystatin was 20{\%} (p = 0.23). We favor ketoconazole as antifungal prophylaxis during antilymphoma chemotherapy because of at least equivalent and possibly superior efficacy, better acceptance by patients, easier administration, and systemic absorption.",
author = "A. Turhan and Connors, {J. M.} and Paul Klimo",
year = "1987",
month = "1",
day = "1",
doi = "10.1097/00000421-198708000-00019",
language = "English (US)",
volume = "10",
pages = "355--359",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy.

AU - Turhan, A.

AU - Connors, J. M.

AU - Klimo, Paul

PY - 1987/1/1

Y1 - 1987/1/1

N2 - We evaluated the efficacy and toxicity of ketoconazole versus nystatin antimycotic prophylaxis in a prospective randomized study of 32 patients receiving intensive weekly outpatient combination chemotherapy for non-Hodgkin's lymphoma with crossover to the other drug if failure occurred. Thirteen patients were assigned to nystatin and 19 to ketoconazole. Fungal infections occurred in three patients receiving nystatin (16%) and one patient receiving ketoconazole (8%); one patient refused his assigned drug due to taste intolerance. Including the crossover courses of drug, the failure rate associated with ketoconazole was 6% while that for nystatin was 20% (p = 0.23). We favor ketoconazole as antifungal prophylaxis during antilymphoma chemotherapy because of at least equivalent and possibly superior efficacy, better acceptance by patients, easier administration, and systemic absorption.

AB - We evaluated the efficacy and toxicity of ketoconazole versus nystatin antimycotic prophylaxis in a prospective randomized study of 32 patients receiving intensive weekly outpatient combination chemotherapy for non-Hodgkin's lymphoma with crossover to the other drug if failure occurred. Thirteen patients were assigned to nystatin and 19 to ketoconazole. Fungal infections occurred in three patients receiving nystatin (16%) and one patient receiving ketoconazole (8%); one patient refused his assigned drug due to taste intolerance. Including the crossover courses of drug, the failure rate associated with ketoconazole was 6% while that for nystatin was 20% (p = 0.23). We favor ketoconazole as antifungal prophylaxis during antilymphoma chemotherapy because of at least equivalent and possibly superior efficacy, better acceptance by patients, easier administration, and systemic absorption.

UR - http://www.scopus.com/inward/record.url?scp=0023395858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023395858&partnerID=8YFLogxK

U2 - 10.1097/00000421-198708000-00019

DO - 10.1097/00000421-198708000-00019

M3 - Article

VL - 10

SP - 355

EP - 359

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -